Obesity Management

EASO Framework for the Pharmacological Treatment of Obesity

by Prateek Chopra | June 12, 2026 | Cardiology Conferences | ESH 2026 Personalized Obesity Care: Obesity is a chronic, relapsing adiposity-based disease leading to mechanical and metabolic complications via complex genetic, biological, and environmental interactions. Effective management requires a patient-centered approach combining lifestyle interventions, nutrition, physical activity, pharmacotherapy, and bariatric surgery when appropriate. Evidence-Based Framework: Treatment Principles: Key Insights & […]

EASO Framework for the Pharmacological Treatment of Obesity Read Post »

Leave a Comment / ESH Day 3 / bluetree.healthcare@gmail.com / July 29, 2026 / Anti-Obesity Medications, EASO 2025 Guidelines, Obesity Management, Personalized Obesity Treatment, Tirzepatide

TRIUMPH-1 Trial: Results of First Phase 3 Study of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist in Patients with Obesity

by Prateek Chopra | June 29, 2026 | Diabetes Conferences | ADA 2026 Therapeutic Overview TRIUMPH-1 Trial Design Weight Loss Outcomes Impact on Obesity Status Cardiometabolic Benefits Effects on Obesity-Related Conditions Clinical Implications In the phase 3 TRIUMPH-1 trial, retatrutide produced marked and sustained weight loss, with many participants no longer meeting criteria for obesity after treatment. The associated improvements

TRIUMPH-1 Trial: Results of First Phase 3 Study of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist in Patients with Obesity Read Post »

Leave a Comment / Diabetes Conferences / bluetree.healthcare@gmail.com / July 29, 2026 / ADA 2026, Obesity Management, Retatrutide, Triple Receptor Agonist, TRIUMPH-1 Trial, Weight Loss Therapy

A1C and BMI Changes by Sociodemographic Groups Among Patients UsingGLP-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors(SGLT-2i) in a Large Integrated Health System

by Prateek Chopra | June 23, 2026 | Diabetes Conferences | ADA 2026 | 0 comments Clinical Relevance Methods Study Population Glycemic and Weight Outcomes Differences Across Demographic Groups Clinical Implications In a real-world healthcare setting, GLP-1 RA therapy was associated with clinically meaningful reductions in HbA1c and BMI among patients with T2DM and obesity. Greater benefits observed in specific racial, ethnic,

A1C and BMI Changes by Sociodemographic Groups Among Patients UsingGLP-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors(SGLT-2i) in a Large Integrated Health System Read Post »

Leave a Comment / Diabetes Conferences / bluetree.healthcare@gmail.com / July 28, 2026 / ADA 2026, GLP-1 Receptor Agonists, HbA1c and Weight Loss, Obesity Management, Real-World Diabetes Research, Type 2 Diabetes (T2DM)